Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine plus dexamethasone for inoperable malignant bowel obstruction
ACTRN12621001403820Phase 2Terminated
- Sponsor
- University of Technology Sydney
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malignant bowel obstruction (MBO) comparing Famotidine + dexamethasone + isotonic fluids with Placebo + dexamethasone + isotonic fluids (2 arms). Primary endpoint: Feasibility for phase III trial. Started Feb 2022; status: terminated.
02
Drugs
famotidinedexamethasone
03
Conditions
malignant bowel obstruction (MBO)
Beyond the preview
Go deeper on ACTRN12621001403820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001403820.